VivoSim Labs, Inc. (VIVS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, VivoSim Labs, Inc. (VIVS) has a cash flow conversion efficiency ratio of 1.370x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.21 Million) by net assets ($-2.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see VivoSim Labs, Inc. market cap and net worth for the company's overall valuation and market capitalisation.
VivoSim Labs, Inc. - Cash Flow Conversion Efficiency Trend (2011–2026)
This chart illustrates how VivoSim Labs, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
VivoSim Labs, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of VivoSim Labs, Inc. ranked by their cash flow conversion efficiency. Explore VIVS cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PROSPECT RIDGE RESOURCES
F:0ED
|
-0.292x |
|
Omnia Metals Group Ltd
AU:OM1
|
-0.055x |
|
Centogene N.V.
NASDAQ:CNTGF
|
N/A |
|
Forterra PLC
LSE:FORT
|
0.109x |
|
Co-Diagnostics, Inc. Common Stock
NASDAQ:CODX
|
-0.489x |
|
Alvo Minerals Ltd
AU:ALV
|
-2.176x |
|
Pool Safe Inc
V:POOL
|
-3.557x |
|
Fancy Wood Industries Public Company Limited
BK:FANCY
|
0.011x |
Annual Cash Flow Conversion Efficiency for VivoSim Labs, Inc. (2011–2026)
The table below shows the annual cash flow conversion efficiency of VivoSim Labs, Inc. from 2011 to 2026. View VivoSim Labs, Inc. (VIVS) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | $-1.10 Million | $-10.83 Million | 9.852x | +1192.53% |
| 2025-03-31 | $10.49 Million | $-9.46 Million | -0.902x | +77.84% |
| 2024-03-31 | $3.60 Million | $-14.65 Million | -4.069x | -402.71% |
| 2023-03-31 | $15.33 Million | $-12.41 Million | -0.809x | -189.28% |
| 2022-03-31 | $30.21 Million | $-8.45 Million | -0.280x | +17.68% |
| 2021-03-31 | $39.20 Million | $-13.32 Million | -0.340x | +39.17% |
| 2020-03-31 | $26.63 Million | $-14.88 Million | -0.559x | +0.45% |
| 2019-03-31 | $36.30 Million | $-20.38 Million | -0.561x | +13.27% |
| 2018-03-31 | $44.59 Million | $-28.86 Million | -0.647x | -38.30% |
| 2017-03-31 | $62.36 Million | $-29.18 Million | -0.468x | +0.91% |
| 2016-03-31 | $62.18 Million | $-29.37 Million | -0.472x | -17.34% |
| 2015-03-31 | $48.70 Million | $-19.60 Million | -0.403x | -24.90% |
| 2014-03-31 | $48.28 Million | $-15.56 Million | -0.322x | -117.63% |
| 2013-03-31 | $-5.30 Million | $-9.69 Million | 1.828x | -89.28% |
| 2011-03-31 | $-6.42K | $-109.42K | 17.052x | -- |
About VivoSim Labs, Inc.
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models. The company also provides liver toxicology predictive screening and research services, as well as… Read more